C. Greg Guyer, Ph.D., is a distinguished figure in the biotechnology industry, currently serving as the Executive Vice President and Chief Technical Officer at BioMarin Pharmaceutical Inc. With a robust academic background, Dr. Guyer holds a Ph.D. in biochemistry from the University of California, Berkeley. His career spans over three decades, during which he has held pivotal roles in both research and development, as well as in operational leadership. Before joining BioMarin, Dr. Guyer worked at Genentech, where he was instrumental in the development and commercialization of several groundbreaking biologics, significantly impacting the treatment landscape for various diseases. At BioMarin, Dr. Guyer has been a driving force behind the company's success in developing and delivering innovative therapies for rare genetic diseases. In his role as Chief Technical Officer, he oversees the technical operations, which include manufacturing, process development, and quality assurance. His strategic vision and technical expertise have been crucial in scaling up BioMarin's production capabilities to meet global demand for their therapies. Under his leadership, BioMarin has successfully navigated the complex regulatory landscape, securing approvals for several new drugs that have transformed the lives of patients worldwide. Dr. Guyer's contributions to the field extend beyond his corporate role; he is also an active member of several scientific and industry organizations, where he shares his insights and helps shape the future of biotechnology. His work has been recognized with numerous awards and accolades, reflecting his commitment to advancing medical science and improving patient outcomes. As BioMarin continues to expand its portfolio and reach, Dr. Guyer's leadership remains a cornerstone of the company's mission to bring novel treatments to those in need.